ArticleCancer biology & therapy2020

A novel non-agonist c-Met antibody drug conjugate with superior potency over a c-Met tyrosine kinase inhibitor in c-Met amplified and non-amplified cancers.

Ryo Fujita et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.